Astrazeneca Plc ADR (AZN)

$83.29 -0.11 (-0.13%)
Market Cap 258.66B
Revenue (ttm) 54.07B
Net Income (ttm) 7.04B
EPS (ttm) N/A
PE Ratio 18.88
Forward PE 18.29
Profit Margin 13.01%
Debt to Equity Ratio 0.70
Volume 2,380,300
Avg Vol 4,663,632
Day's Range N/A - N/A
Shares Out 3.10B
Stochastic %K 16%
Beta 0.36
Analysts Strong Sell
Price Target $85.59

Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modi...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 44 20 3749 5000
Fax: 44 1223 352 858
Address:
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 24 at 11:30 PM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $AZN Current Share Price: $83.34 Contracts: $AZN January 15, 2027 $85 Calls Scale in: $8.47- $10.35 Scale out: $13.18-$16.94 Can Easily Capture: 60% ROI Blended DTE: 449 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
Orange_Shark
Orange_Shark Oct. 22 at 7:29 PM
$NVAX Looks like an $AZN buyout soon
0 · Reply
InfinityVenom
InfinityVenom Oct. 22 at 2:28 PM
$AZN Unstoppable
0 · Reply
TheRealShortSqueezy
TheRealShortSqueezy Oct. 22 at 2:04 PM
$OSTX Advancing hope in the fight against cancer 🧬 OS Therapies is a clinical-stage biotech company pioneering immunotherapy breakthroughs for osteosarcoma and other solid tumors, bringing new options to patients facing limited treatments. 📰News today: OS Therapies Announces Overall and Event Free Survival Key Subgroup Data for OST-HER2 in Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma With a Final Type C Meeting scheduled with the FDA on December 11, 2025 and a pre-MAA meeting granted by the U.K. MHRA, OS Therapies moves closer to potential regulatory milestones for its OST-HER2 program. 📊Technical view: - Key support $1.X.74 - Key levels on upside breakouts: $1.X.96 ➡️ $2.X.11➡️$2.X.25 ➡️ $2.X.36 ➡️ $2.X.52 News link : https://tinyurl.com/mvp66br5 Communicated Disclaimer: https://stockresearchtoday.com/groundbreaking-treatments-for-solid-tumors/ Sector Peers: $GMAB $AZN $PFE $ABBV
0 · Reply
Ilikethestock89
Ilikethestock89 Oct. 22 at 1:50 PM
$AZN $NVAX max 30
0 · Reply
wamomo
wamomo Oct. 22 at 1:48 PM
$NVAX $AZN has a market cap of $259 billion. What would they pay for Novavax?
2 · Reply
MrCompassion
MrCompassion Oct. 22 at 12:53 PM
$IFRX I’ve been thinking lately about the potential of an $AZN AstraZeneca/InflaRx partnership as to expanding INF904 R&D. Just so happened that earlier today I scanned a recent pub, about the activity of NETs in cancer, then just now came across this interview linking it all together. Would be great to see pipeline expansion into this important area of study, really spotlight the game-changing potential of C5a/R signaling control biotech. No active neutrophils, no NETs. Controlled C5a–C5aR1 signaling, controlled NETosis. The role of NETosis in breast cancer: mechanistic insights and biomarker potential https://breast-cancer-research.biomedcentral.com/articles/10.1186/s13058-025-02136-0 AstraZeneca CEO on breast cancer drug trial https://www.youtube.com/watch?v=1WwIPwIcxKE
1 · Reply
dogDazeSummer
dogDazeSummer Oct. 22 at 12:29 PM
@cielo1 @koloops Govt shutdown is irrelevant to $IFRX pending announcement- if we were seeking fda approval - it might matter / delay. Govt will reopen later this week / early next. The airport security people are stopping coming to work - once air travel gets interrupted, the crooked politicians will quickly make a deal. TSA employees didn’t get paid last Tuesday. They already make very little money so some are now driving $UBER Wonder what BP is interested in PG? Maybe $AZN ?
1 · Reply
lecorb
lecorb Oct. 22 at 12:14 PM
$NVAX $AZN Novavax to assign Gaithersburg, Md. facility to AstraZeneca in $60B deal https://seekingalpha.com/news/4506596-novavax-assigns-gaithersburg-md-site-astrazeneca?mailingid=42111633&messageid=2900&position=rta_news_most_popular_main_0_title&serial=42111633.2243&source=email_2900&utm_campaign=rta-stock-news&utm_content=link-1&utm_medium=email&utm_source=seeking_alpha&utm_term=42111633.2243
2 · Reply
dogDazeSummer
dogDazeSummer Oct. 22 at 11:18 AM
$IFRX Lots of cash on sidelines for big pharmaceutical entities according to new data out from Leerink: Not to mention $XBI flying 52wk highs creating daily increase in currency. Cash + Currency does imply M&A. $PFE $RHHBY $AZN
0 · Reply
Latest News on AZN
AstraZeneca found in breach of industry code over Symbicort marketing, industry body says

Oct 24, 2025, 4:51 AM EDT - 1 day ago

AstraZeneca found in breach of industry code over Symbicort marketing, industry body says

AstraZeneca hails major breakthroughs with breast-cancer drugs

Oct 20, 2025, 6:53 AM EDT - 5 days ago

AstraZeneca hails major breakthroughs with breast-cancer drugs

AstraZeneca's Datroway extends survival in aggressive breast cancer

Oct 19, 2025, 2:32 AM EDT - 6 days ago

AstraZeneca's Datroway extends survival in aggressive breast cancer

AstraZeneca's Enhertu shows promise in early-stage breast cancer treatment

Oct 18, 2025, 10:33 AM EDT - 6 days ago

AstraZeneca's Enhertu shows promise in early-stage breast cancer treatment

TEZSPIRE approved in the US for chronic rhinosinusitis with nasal polyps

Oct 17, 2025, 4:17 PM EDT - 7 days ago

TEZSPIRE approved in the US for chronic rhinosinusitis with nasal polyps

US FDA expands use of Amgen, AstraZeneca's drug for sinus infection

Oct 17, 2025, 4:08 PM EDT - 7 days ago

US FDA expands use of Amgen, AstraZeneca's drug for sinus infection

AMGN

AstraZeneca unveils expanded manufacturing facility in Texas

Oct 15, 2025, 10:00 AM EDT - 9 days ago

AstraZeneca unveils expanded manufacturing facility in Texas

AstraZeneca furthers ambition to redefine cancer care with first data from four major pivotal trials at ESMO

Oct 13, 2025, 7:00 AM EDT - 12 days ago

AstraZeneca furthers ambition to redefine cancer care with first data from four major pivotal trials at ESMO

Banquets and billions: How AstraZeneca sealed a US medicine deal with Trump

Oct 12, 2025, 9:25 AM EDT - 12 days ago

Banquets and billions: How AstraZeneca sealed a US medicine deal with Trump

Trump announces drug-pricing deal with pharma giant

Oct 10, 2025, 7:30 PM EDT - 14 days ago

Trump announces drug-pricing deal with pharma giant

Trump reaches deal with AstraZeneca to lower U.S. drug prices

Oct 10, 2025, 6:30 PM EDT - 14 days ago

Trump reaches deal with AstraZeneca to lower U.S. drug prices

AstraZeneca Cuts Discounted Drug Pricing Deal With the White House. The Stock Is Rising.

Oct 10, 2025, 6:23 PM EDT - 14 days ago

AstraZeneca Cuts Discounted Drug Pricing Deal With the White House. The Stock Is Rising.

Pres. Trump announces deal with AstraZeneca to lower U.S. drug prices

Oct 10, 2025, 6:17 PM EDT - 14 days ago

Pres. Trump announces deal with AstraZeneca to lower U.S. drug prices

TrumpRx makes more drug pricing moves and strikes a deal with AstraZeneca

Oct 10, 2025, 6:05 PM EDT - 14 days ago

TrumpRx makes more drug pricing moves and strikes a deal with AstraZeneca

Trump says AstraZeneca to offer drugs to US at discounted prices

Oct 10, 2025, 5:54 PM EDT - 14 days ago

Trump says AstraZeneca to offer drugs to US at discounted prices

AstraZeneca to become latest drugmaker to strike deal with Trump. Its stock is down but outperforming the market.

Oct 10, 2025, 3:45 PM EDT - 14 days ago

AstraZeneca to become latest drugmaker to strike deal with Trump. Its stock is down but outperforming the market.

AstraZeneca is the latest major drugmaker to strike a deal with the Trump administration on lowering U.S. drug prices, according to a person familiar with the matter

Oct 10, 2025, 3:45 PM EDT - 14 days ago

AstraZeneca is the latest major drugmaker to strike a deal with the Trump administration on lowering U.S. drug prices, according to a person familiar with the matter

Trump reaches deal with AstraZeneca to lower U.S. drug prices, MSNBC reports

Oct 10, 2025, 2:53 PM EDT - 14 days ago

Trump reaches deal with AstraZeneca to lower U.S. drug prices, MSNBC reports

Next medicine deal after Pfizer? Analysts, shares point to AstraZeneca, Eli Lilly

Oct 10, 2025, 10:15 AM EDT - 14 days ago

Next medicine deal after Pfizer? Analysts, shares point to AstraZeneca, Eli Lilly

LLY

AstraZeneca breaks ground at $4.5 billion Virginia plant as drugmakers court Trump

Oct 9, 2025, 12:32 PM EDT - 15 days ago

AstraZeneca breaks ground at $4.5 billion Virginia plant as drugmakers court Trump

AstraZeneca plans to increase investment and scope of its Virginia manufacturing facility to $4.5 billion, creating 3,600 new jobs

Oct 9, 2025, 12:30 PM EDT - 15 days ago

AstraZeneca plans to increase investment and scope of its Virginia manufacturing facility to $4.5 billion, creating 3,600 new jobs

Turbine Launches Collaboration with AstraZeneca, Leveraging Turbine's Virtual Disease Models to Rationalize ADC Discovery

Oct 9, 2025, 6:00 AM EDT - 16 days ago

Turbine Launches Collaboration with AstraZeneca, Leveraging Turbine's Virtual Disease Models to Rationalize ADC Discovery

Baxdrostat met the primary endpoint in Bax24 Phase III trial in patients with resistant hypertension

Oct 7, 2025, 7:00 AM EDT - 18 days ago

Baxdrostat met the primary endpoint in Bax24 Phase III trial in patients with resistant hypertension

AstraZeneca's Baxdrostat meets main goal in high blood pressure study

Oct 7, 2025, 2:14 AM EDT - 18 days ago

AstraZeneca's Baxdrostat meets main goal in high blood pressure study

My Top 5 Biotech Stocks Big Pharma Could Buy Next

Oct 6, 2025, 1:29 PM EDT - 18 days ago

My Top 5 Biotech Stocks Big Pharma Could Buy Next

ABBV ALVO AMGN ARKG BIIB BMY GILD

AstraZeneca signs up to $555 million deal with US-based Algen to develop gene therapies

Oct 6, 2025, 8:04 AM EDT - 19 days ago

AstraZeneca signs up to $555 million deal with US-based Algen to develop gene therapies

Algen Biotechnologies Announces Multi-Target Partnership to Advance AI-Powered Drug Discovery in Immunology with AstraZeneca

Oct 6, 2025, 8:00 AM EDT - 19 days ago

Algen Biotechnologies Announces Multi-Target Partnership to Advance AI-Powered Drug Discovery in Immunology with AstraZeneca

AstraZeneca inks $555 million gene-editing technology deal with Algen, FT reports

Oct 6, 2025, 5:25 AM EDT - 19 days ago

AstraZeneca inks $555 million gene-editing technology deal with Algen, FT reports

AstraZeneca's Datroway boosts survival in advanced breast cancer trial

Oct 6, 2025, 2:57 AM EDT - 19 days ago

AstraZeneca's Datroway boosts survival in advanced breast cancer trial

Pharmaceutical Stocks: Valuations And Pipelines Are Only Beginning To Be Appreciated

Oct 3, 2025, 4:20 PM EDT - 21 days ago

Pharmaceutical Stocks: Valuations And Pipelines Are Only Beginning To Be Appreciated

LLY NVO PFE

AstraZeneca shares leap with FDA set to review drug to treat breast cancer

Oct 1, 2025, 10:54 AM EDT - 23 days ago

AstraZeneca shares leap with FDA set to review drug to treat breast cancer

CNBC's UK Exchange newsletter: AstraZeneca gets a shot on Wall Street

Oct 1, 2025, 1:30 AM EDT - 24 days ago

CNBC's UK Exchange newsletter: AstraZeneca gets a shot on Wall Street

AstraZeneca's US listing may pull other firms from London in its wake

Sep 30, 2025, 10:29 AM EDT - 24 days ago

AstraZeneca's US listing may pull other firms from London in its wake

AstraZeneca plans to list on NYSE, but will remain in the U.K.

Sep 29, 2025, 2:52 PM EDT - 25 days ago

AstraZeneca plans to list on NYSE, but will remain in the U.K.

Pharma giant AstraZeneca eyes NYSE listing overhaul, keeps London base

Sep 29, 2025, 4:43 AM EDT - 26 days ago

Pharma giant AstraZeneca eyes NYSE listing overhaul, keeps London base

AstraZeneca to directly list shares in New York, retain UK listing

Sep 29, 2025, 2:07 AM EDT - 26 days ago

AstraZeneca to directly list shares in New York, retain UK listing

Pharma tariffs 'not a huge risk' for domestic companies, says Mizuho's Jared Holz

Sep 26, 2025, 6:39 PM EDT - 4 weeks ago

Pharma tariffs 'not a huge risk' for domestic companies, says Mizuho's Jared Holz

LLY MRK NVO PFE ROG

A New Prescription For Pain: Understanding Trump's 100% Pharma Tariff

Sep 26, 2025, 2:37 PM EDT - 4 weeks ago

A New Prescription For Pain: Understanding Trump's 100% Pharma Tariff

LLY NVO SNY

AstraZeneca to Offer Discounted Drugs As Trump Pressures Pharma Industry to Cut Prices

Sep 26, 2025, 11:43 AM EDT - 4 weeks ago

AstraZeneca to Offer Discounted Drugs As Trump Pressures Pharma Industry to Cut Prices

AstraZeneca launches direct-to-consumer platform to expand access to medications for US patients, including those living with chronic conditions

Sep 26, 2025, 9:00 AM EDT - 4 weeks ago

AstraZeneca launches direct-to-consumer platform to expand access to medications for US patients, including those living with chronic conditions

AstraZeneca to cut some direct-to-patient US drug prices after Trump demand

Sep 26, 2025, 8:53 AM EDT - 4 weeks ago

AstraZeneca to cut some direct-to-patient US drug prices after Trump demand

AstraZeneca: Oncology Breakthroughs And Farxiga Surge Excite Investors

Sep 25, 2025, 8:45 AM EDT - 4 weeks ago

AstraZeneca: Oncology Breakthroughs And Farxiga Surge Excite Investors

ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab granted Priority Review in the US as 1st-line treatment for patients with HER2-positive metastatic breast cancer

Sep 24, 2025, 7:00 AM EDT - 4 weeks ago

ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab granted Priority Review in the US as 1st-line treatment for patients with HER2-positive metastatic breast cancer

European Advisory Panel Recommends Two AstraZeneca Drugs For Approval

Sep 22, 2025, 2:20 PM EDT - 4 weeks ago

European Advisory Panel Recommends Two AstraZeneca Drugs For Approval

SOPHiA GENETICS Expands Collaboration with AstraZeneca to Enhance Detection of Breast and Prostate Cancer

Sep 22, 2025, 8:00 AM EDT - 4 weeks ago

SOPHiA GENETICS Expands Collaboration with AstraZeneca to Enhance Detection of Breast and Prostate Cancer

SOPH

Bloomberg Dividend Watchlist's 4 Ideal 'Safer' September Sizzlers

Sep 20, 2025, 3:38 AM EDT - 5 weeks ago

Bloomberg Dividend Watchlist's 4 Ideal 'Safer' September Sizzlers

AVGO CL CP EMR ESS FOX KLAC

3 Potential Biotech Acquisition Targets

Sep 19, 2025, 12:53 PM EDT - 5 weeks ago

3 Potential Biotech Acquisition Targets

ETNB INCY MLYS SNDX TVTX

AstraZeneca: Consistent Growth And Upcoming Catalysts Make This A Buy

Sep 19, 2025, 9:30 AM EDT - 5 weeks ago

AstraZeneca: Consistent Growth And Upcoming Catalysts Make This A Buy

AstraZeneca's Fasenra Falls Short In Smoker's Lung Trial

Sep 17, 2025, 1:20 PM EDT - 5 weeks ago

AstraZeneca's Fasenra Falls Short In Smoker's Lung Trial

SAPHNELO self-administration TULIP-SC Phase III trial meets primary endpoint in patients with systemic lupus erythematosus based on an interim analysis

Sep 17, 2025, 7:05 AM EDT - 5 weeks ago

SAPHNELO self-administration TULIP-SC Phase III trial meets primary endpoint in patients with systemic lupus erythematosus based on an interim analysis

LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 24 at 11:30 PM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $AZN Current Share Price: $83.34 Contracts: $AZN January 15, 2027 $85 Calls Scale in: $8.47- $10.35 Scale out: $13.18-$16.94 Can Easily Capture: 60% ROI Blended DTE: 449 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
Orange_Shark
Orange_Shark Oct. 22 at 7:29 PM
$NVAX Looks like an $AZN buyout soon
0 · Reply
InfinityVenom
InfinityVenom Oct. 22 at 2:28 PM
$AZN Unstoppable
0 · Reply
TheRealShortSqueezy
TheRealShortSqueezy Oct. 22 at 2:04 PM
$OSTX Advancing hope in the fight against cancer 🧬 OS Therapies is a clinical-stage biotech company pioneering immunotherapy breakthroughs for osteosarcoma and other solid tumors, bringing new options to patients facing limited treatments. 📰News today: OS Therapies Announces Overall and Event Free Survival Key Subgroup Data for OST-HER2 in Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma With a Final Type C Meeting scheduled with the FDA on December 11, 2025 and a pre-MAA meeting granted by the U.K. MHRA, OS Therapies moves closer to potential regulatory milestones for its OST-HER2 program. 📊Technical view: - Key support $1.X.74 - Key levels on upside breakouts: $1.X.96 ➡️ $2.X.11➡️$2.X.25 ➡️ $2.X.36 ➡️ $2.X.52 News link : https://tinyurl.com/mvp66br5 Communicated Disclaimer: https://stockresearchtoday.com/groundbreaking-treatments-for-solid-tumors/ Sector Peers: $GMAB $AZN $PFE $ABBV
0 · Reply
Ilikethestock89
Ilikethestock89 Oct. 22 at 1:50 PM
$AZN $NVAX max 30
0 · Reply
wamomo
wamomo Oct. 22 at 1:48 PM
$NVAX $AZN has a market cap of $259 billion. What would they pay for Novavax?
2 · Reply
MrCompassion
MrCompassion Oct. 22 at 12:53 PM
$IFRX I’ve been thinking lately about the potential of an $AZN AstraZeneca/InflaRx partnership as to expanding INF904 R&D. Just so happened that earlier today I scanned a recent pub, about the activity of NETs in cancer, then just now came across this interview linking it all together. Would be great to see pipeline expansion into this important area of study, really spotlight the game-changing potential of C5a/R signaling control biotech. No active neutrophils, no NETs. Controlled C5a–C5aR1 signaling, controlled NETosis. The role of NETosis in breast cancer: mechanistic insights and biomarker potential https://breast-cancer-research.biomedcentral.com/articles/10.1186/s13058-025-02136-0 AstraZeneca CEO on breast cancer drug trial https://www.youtube.com/watch?v=1WwIPwIcxKE
1 · Reply
dogDazeSummer
dogDazeSummer Oct. 22 at 12:29 PM
@cielo1 @koloops Govt shutdown is irrelevant to $IFRX pending announcement- if we were seeking fda approval - it might matter / delay. Govt will reopen later this week / early next. The airport security people are stopping coming to work - once air travel gets interrupted, the crooked politicians will quickly make a deal. TSA employees didn’t get paid last Tuesday. They already make very little money so some are now driving $UBER Wonder what BP is interested in PG? Maybe $AZN ?
1 · Reply
lecorb
lecorb Oct. 22 at 12:14 PM
$NVAX $AZN Novavax to assign Gaithersburg, Md. facility to AstraZeneca in $60B deal https://seekingalpha.com/news/4506596-novavax-assigns-gaithersburg-md-site-astrazeneca?mailingid=42111633&messageid=2900&position=rta_news_most_popular_main_0_title&serial=42111633.2243&source=email_2900&utm_campaign=rta-stock-news&utm_content=link-1&utm_medium=email&utm_source=seeking_alpha&utm_term=42111633.2243
2 · Reply
dogDazeSummer
dogDazeSummer Oct. 22 at 11:18 AM
$IFRX Lots of cash on sidelines for big pharmaceutical entities according to new data out from Leerink: Not to mention $XBI flying 52wk highs creating daily increase in currency. Cash + Currency does imply M&A. $PFE $RHHBY $AZN
0 · Reply
topstockalerts
topstockalerts Oct. 20 at 11:40 PM
Fredrickson shared details of three major breast cancer trials of drugs known as antibody drug conjugates (or ADCs), a more precise, targeted type of “smart chemotherapy.” Testing has shown them to make significant advances in the mitigation and elimination of breast cancer, or materially extending life expectancy in the most difficult category of cancer, the triple or fully negative. The first trial discussed was DESTINY-Breast05 studying Enhertu, which in trials reduced the risk of disease recurrence by half, compared to the T-DM1 treatment currently offered to patients with early-stage breast cancer. Fredrickson noted that early-stage breast cancer is anything below stage four. More than 92% of patients treated with Enhertu, a drug AstraZeneca developed in partnership with Japan’s Daiichi Sankyo 4568 +2.70% , were alive and free of invasive disease after three years. $AZN
0 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 20 at 9:44 PM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $AZN Current Share Price: $84.69 Contracts: $AZN January 15, 2027 $85 Calls Scale in: $9.34- $11.41 Scale out: $14.52-$18.68 Can Easily Capture: 60% ROI Blended DTE: 453 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
TechTraderGrok
TechTraderGrok Oct. 20 at 8:41 PM
Sold $AZN at $83.87 (+0.3%). From Grok: "AZN's uptrend remains intact with price above EMA and SMA, but recent pullback below short-term support near $85 amid fading momentum and upcoming earnings on 11/6/2025 without qualifying positive surprise history prompts exit from long position to lock in small gains and avoid volatility risk." https://www.techtrader.ai/grokwall/?post=15281&utm_source=dlvr.it&utm_medium=stocktwits
0 · Reply
Quantumup
Quantumup Oct. 20 at 6:46 PM
Piper Sandler reiterated $UPB Overweight-$75 and said UPB has traded up ~130%+ over the last 6-months where verekitug (TSLP-R mAb) showed compelling efficacy/safety in Ph2 VIBRANT CRSwNP with upcoming Ph2 VALIANT severe asthma topline 1Q26 (~Feb/Mar 2026, per our math). $AMGN - $AZN $REGN - $SNY Piper Sandler added:
0 · Reply
Quantumup
Quantumup Oct. 20 at 5:58 PM
Needham⬆️ $CELC's PT to $95 from $70, reiterated at Buy, and said that it considers updated gedatolisib results from the PIK3CA wild-type cohort of the pivotal VIKTORIA-1 study as further de-risking and potentially practice-changing—thinks a lack of PFS benefit observed for $RHHBY's oral SERD giredestrant in ESR1 WT patients removes an overhang on CELC. $PFE $AZN
0 · Reply
StocktwitsNews
StocktwitsNews Oct. 20 at 9:41 AM
AstraZeneca’s Enhertu Achieves Record Response Rate In Phase 3 Trial For Early Breast Cancer $AZN https://stocktwits.com/news/equity/markets/astra-zeneca-s-enhertu-achieves-record-response-rate-in-phase-3-trial-for-early-breast-cancer/ch6Co1JR3Ya
0 · Reply
TalkMarkets
TalkMarkets Oct. 19 at 9:37 AM
Should You Buy, Sell Or Hold J&J Stock After Robust Q3 Earnings? $JNJ Also $AZN $PFE https://talkmarkets.com/content/stocks--equities/should-you-buy-sell-or-hold-jj-stock-after-robust-q3-earnings?post=529313
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Oct. 18 at 6:50 PM
$AZN
0 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 18 at 12:35 PM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $AZN Current Share Price: $83.83 Contracts: $AZN January 15, 2027 $85 Calls Scale in: $10.35- $12.65 Scale out: $16.10-$20.70 Can Easily Capture: 60% ROI Blended DTE: 455 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Oct. 17 at 10:07 PM
$AMGN $AZN
0 · Reply
miggy99
miggy99 Oct. 17 at 8:29 PM
$AZN https://finance.yahoo.com/news/tezspire-approved-us-chronic-rhinosinusitis-201700787.html
0 · Reply
muhammadhc93
muhammadhc93 Oct. 17 at 7:14 PM
$AZN This summit is the right room for a CRC prevention pitch. AA 82 percent means preventing cancer not just detecting it. Health economic models reward prevention. Funds at Maxim understand payer math
0 · Reply